Umeå universitets logga

umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
COVIDENZA - A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19): a structured summary of a study protocol for a randomised controlled trial
Department of Urology/Sahlgrenska Center for Cancer Research, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Umeå universitet, Medicinska fakulteten, Molekylär Infektionsmedicin, Sverige (MIMS). Umeå universitet, Medicinska fakulteten, Institutionen för klinisk mikrobiologi, Avdelningen för virologi.ORCID-id: 0000-0001-6553-0940
Umeå universitet, Medicinska fakulteten, Institutionen för klinisk mikrobiologi.
Department of Medical Sciences, National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Visa övriga samt affilieringar
2021 (Engelska)Ingår i: Trials, E-ISSN 1745-6215, Vol. 22, nr 1, artikel-id 209Artikel i tidskrift, Letter (Refereegranskat) Published
Abstract [en]

Objectives: The main goal of the COVIDENZA trial is to evaluate if inhibition of testosterone signalling by enzalutamide can improve the outcome of patients hospitalised for COVID-19. The hypothesis is based on the observation that the majority of patients in need of intensive care are male, and the connection between androgen receptor signalling and expression of TMPRSS2, an enzyme important for SARS-CoV-2 host cell internalization.

Trial design: Hospitalised COVID-19 patients will be randomised (2:1) to enzalutamide plus standard of care vs. standard of care designed to identify superiority.

Participants: Included participants, men or women above 50 years of age, must be hospitalised for PCR confirmed COVID-19 symptoms and not in need of immediate mechanical ventilation. Major exclusion criteria are breast-feeding or pregnant women, hormonal treatment for prostate or breast cancer, treatment with immunosuppressive drugs, current symptomatic unstable cardiovascular disease (see Additional file 1 for further details). The trial is registered at Umeå University Hospital, Region Västerbotten, Sweden and 8 hospitals are approved for inclusion in Sweden.

Intervention and comparator: Patients randomised to the treatment arm will be treated orally with 160 mg (4x40 mg) enzalutamide (Xtandi®) daily, for five consecutive days. The study is not placebo controlled. The comparator is standard of care treatment for patients hospitalised with COVID-19.

Main outcomes: The primary endpoints of the study are (time to) need of mechanical ventilation or discharge from hospital as assessed by a clinical 7-point ordinal scale (up to 30 days after inclusion).

Randomisation: Randomisation was stratified by center and sex. Each strata was randomized separately with block size six with a 2:1 allocation ratio (enzalutamide + “standard of care”: “standard of care”). The randomisation list, with consecutive subject numbers, was generated by an independent statistician using the PROC PLAN procedure of SAS version 9.4 software (SAS Institute, Inc, Cary, North Carolina)

Blinding (masking): This is an open-label trial.

Numbers to be randomised (sample size): The trial is designed to have three phases. The first, an exploration phase of 45 participants (30 treatment and 15 control) will focus on safety and includes a more extensive laboratory assessment as well as more frequent safety evaluation. The second prolongation phase, includes the first 100 participants followed by an interim analysis to define the power of the study. The third phase is the continuation of the study up to maximum 600 participants included in total.

Trial Status: The current protocol version is COVIDENZA v2.0 as of September 10, 2020. Recruitment started July 29, 2020 and is presently in safety pause after the first exploration phase. Recruitment is anticipated to be complete by 31 December 2021.

Trial registrationEudract number 2020-002027-10

ClinicalTrials.gov Identifier: NCT04475601, registered June 8, 2020

Full protoco: lThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.

Ort, förlag, år, upplaga, sidor
BioMed Central, 2021. Vol. 22, nr 1, artikel-id 209
Nyckelord [en]
androgen signalling, antiandrogen, COVID-19, enzalutamide, multicentre, protocol, Randomised controlled trial, TMPRSS2
Nationell ämneskategori
Infektionsmedicin
Identifikatorer
URN: urn:nbn:se:umu:diva-181797DOI: 10.1186/s13063-021-05137-4ISI: 000629927400001Scopus ID: 2-s2.0-85102576066OAI: oai:DiVA.org:umu-181797DiVA, id: diva2:1541462
Tillgänglig från: 2021-04-01 Skapad: 2021-04-01 Senast uppdaterad: 2024-01-17Bibliografiskt granskad

Open Access i DiVA

fulltext(416 kB)106 nedladdningar
Filinformation
Filnamn FULLTEXT01.pdfFilstorlek 416 kBChecksumma SHA-512
fae6eb43ee895431f966f285e9a001624467b126c87e8f6d402da9af532ffe90800b277fbb1ad02fb5694ea31d8ac295420832226adf4947f3716e9205f3fe67
Typ fulltextMimetyp application/pdf

Övriga länkar

Förlagets fulltextScopus

Person

Överby, Anna K.Ahlm, ClasAngelin, MartinLindquist, ElisabethBuckland, RobertThellenberg-Karlsson, CamillaStyrke, JohanRepo, Johanna

Sök vidare i DiVA

Av författaren/redaktören
Överby, Anna K.Ahlm, ClasAngelin, MartinLindquist, ElisabethBuckland, RobertThellenberg-Karlsson, CamillaStyrke, JohanRepo, JohannaJosefsson, Andreas
Av organisationen
Molekylär Infektionsmedicin, Sverige (MIMS)Avdelningen för virologiInstitutionen för klinisk mikrobiologiWallenberg centrum för molekylär medicin vid Umeå universitet (WCMM)Urologi och andrologiOnkologi
I samma tidskrift
Trials
Infektionsmedicin

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 106 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

doi
urn-nbn

Altmetricpoäng

doi
urn-nbn
Totalt: 475 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf